Caliway Biopharmaceuticals Co., Ltd.

Caliway Biopharmaceuticals (TWSE: 6919), founded in 2012 in Taiwan, is a biopharmaceutical company developing new drugs for aesthetic medicine and chronic inflammatory diseases. Its lead product CBL-514 induces targeted adipocyte apoptosis at the injection site to effectively reduce subcutaneous fat without damaging surrounding tissues. Publicly traded on the Taiwan Stock Exchange.